Quick Answer
Citrus Bergamot Lipid Profile Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: 1 2 3 Obesity is a multifactorial disease defined as abnormal or excessive fat accumulation that presents a risk to health because it is a major risk factor for several noncommunicable diseases (NCDs), such as cardiovascular diseases, diabetes, and several types of cancer [].
Key Takeaways
- 011 2 3 Obesity is a multifactorial disease defined as abnormal or excessive fat accumulation that presents a risk to health because it is a major risk factor for several noncommunicable diseases (NCDs), such as cardiovascular diseases, diabetes, and several types of cancer []. [Pujia Carmelo (2026)]
- 02Furthermore, obesity and its associated health problems have a significant economic impact on the global healthcare system [,]. [Pujia Carmelo (2026)]
- 03It is well known that a weight loss of between 5% and 10% is sufficient to achieve clinically significant improvements in health risk factors []. [Pujia Carmelo (2026)]
- 04It is a major public health concern that has reached pandemic proportions worldwide. [Pujia Carmelo (2026)]
The current Migaku evidence database contains 2 reusable source documents for Citrus Bergamot Lipid Profile Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- 1 2 3 Obesity is a multifactorial disease defined as abnormal or excessive fat accumulation that presents a risk to health because it is a major risk factor for several noncommunicable diseases (NCDs), such as cardiovascular diseases, diabetes, and several types of cancer []. [Pujia Carmelo (2026); evidence level 1]
- Furthermore, obesity and its associated health problems have a significant economic impact on the global healthcare system [,]. [Pujia Carmelo (2026); evidence level 1]
- It is well known that a weight loss of between 5% and 10% is sufficient to achieve clinically significant improvements in health risk factors []. [Pujia Carmelo (2026); evidence level 1]
- It is a major public health concern that has reached pandemic proportions worldwide. [Pujia Carmelo (2026); evidence level 1]
- Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has emerged as the most prevalent chronic liver disease worldwide, with an overall global prevalence of 30% [...]. [Rodriguez-Ramiro I (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- Effect of Citrus bergamia Supplementation on Body Composition in Humans: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
- Advances in Nutrition for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Current Perspectives from the Bench to the Bedside.